Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Next generation oncology drug development: opportunities and challenges.

Literature DB >> 19390552

Next generation oncology drug development: opportunities and challenges.

Martin E Gutierrez¹, Shivaani Kummar, Giuseppe Giaccone.

Abstract

The optimal development of novel molecularly targeted agents for the treatment of cancer requires a re-evaluation of the current drug development paradigm. Selection of patients, optimal biologic dose versus maximum tolerated dose, definition of response and clinical benefit and trial designs that address these considerations are the focus of debate in the field of early cancer therapeutics. We present a review of the opportunities and challenges facing drug development in oncology through the phases of clinical development starting with first-in-human trials.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2009 PMID： 19390552 PMCID： PMC7079165 DOI： 10.1038/nrclinonc.2009.38

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

43 in total

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506

Review 2. Strategies for optimizing combinations of molecularly targeted anticancer agents.

Authors: Janet E Dancey; Helen X Chen
Journal: Nat Rev Drug Discov Date: 2006-08 Impact factor: 84.694

3. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.

Authors: Gary M Clark; Denni M Zborowski; Pedro Santabarbara; Keyue Ding; Marlo Whitehead; Lesley Seymour; Frances A Shepherd
Journal: Clin Lung Cancer Date: 2006-05 Impact factor: 4.785

4. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

Authors: Walter M Stadler; Gary Rosner; Eric Small; Donna Hollis; Brian Rini; S Donald Zaentz; John Mahoney; Mark J Ratain
Journal: J Clin Oncol Date: 2005-06-01 Impact factor: 44.544

5. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.

Authors: Alex Chang; Purvish Parikh; Sumitra Thongprasert; Eng Huat Tan; Reury-Perng Perng; Domingo Ganzon; Chih-Hsin Yang; Chao-Jung Tsao; Claire Watkins; Nick Botwood; Nick Thatcher
Journal: J Thorac Oncol Date: 2006-10 Impact factor: 15.609

6. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531

7. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Authors: Floriana Morgillo; Woo-Young Kim; Edward S Kim; Fortunato Ciardiello; Waun Ki Hong; Ho-Young Lee
Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531

Review 8. Specific targeted therapy of chronic myelogenous leukemia with imatinib.

Authors: Michael W N Deininger; Brian J Druker
Journal: Pharmacol Rev Date: 2003-07-17 Impact factor: 25.468

9. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors: Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal: J Clin Oncol Date: 2003-05-14 Impact factor: 44.544

10. Designing phase 0 cancer clinical trials.

Authors: Anthony J Murgo; Shivaani Kummar; Larry Rubinstein; Martin Gutierrez; Jerry Collins; Robert Kinders; Ralph E Parchment; Jiuping Ji; Seth M Steinberg; Sherry X Yang; Melinda Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James H Doroshow
Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531

19 in total

1. A Time-Trend Economic Analysis of Cancer Drug Trials.

Authors: Sonya Cressman; George P Browman; Jeffrey S Hoch; Laurel Kovacic; Stuart J Peacock
Journal: Oncologist Date: 2015-06-01

2. Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study.

Authors: Ming-Liang He; Ying Chen; Quan Chen; Yaqing He; Jing Zhao; Jun Wang; Huanming Yang; Hsiang-Fu Kung
Journal: Am J Cancer Res Date: 2011-03-30 Impact factor: 6.166

Review 3. A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

Authors: L Jones; H Carol; K Evans; J Richmond; P J Houghton; M A Smith; R B Lock
Journal: Leukemia Date: 2016-07-15 Impact factor: 11.528

4. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Authors: David A Reardon; Charles A Conrad; Timothy Cloughesy; Michael D Prados; Henry S Friedman; Kenneth D Aldape; Paul Mischel; Jane Xia; Clifford DiLea; Jerry Huang; William Mietlowski; Margaret Dugan; Wei Chen; W K Alfred Yung
Journal: Cancer Chemother Pharmacol Date: 2012-03-07 Impact factor: 3.333

Review 5. Methodological and practical challenges for personalized cancer therapies.

Authors: Ignacio I Wistuba; Juri G Gelovani; Jörg J Jacoby; Suzanne E Davis; Roy S Herbst
Journal: Nat Rev Clin Oncol Date: 2011-03 Impact factor: 66.675

6. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Authors: Apurva K Srivastava; Melinda G Hollingshead; Jeevan Prasaad Govindharajulu; Joseph M Covey; Dane Liston; Melanie A Simpson; James O Peggins; Donald P Bottaro; John J Wright; Robert J Kinders; James H Doroshow; Ralph E Parchment
Journal: Mol Cancer Ther Date: 2018-02-14 Impact factor: 6.261